
BioNTech (BNTX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q3 | Nov 3, 2026 | $2.03 | $0.97 | 109.3 % |
| Q2 | Aug 4, 2026 | $-2.58 | $-2.34 | -10.3 % |
| Q1 | May 5, 2026 | $-2.28 | $-2.52 | 9.52 % |
| Q4 | Mar 10, 2026 | $-0.38 | $-0.47 | 19.1 % |
Quarterly Revenue (Billions)
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q3 | Nov 3, 2026 | $1.48B | $1.17B | 26.8 % |
| Q2 | Aug 4, 2026 | $122.77M | $182.02M | -32.6 % |
| Q1 | May 5, 2026 | $138.00M | $214.62M | -35.7 % |
| Q4 | Mar 10, 2026 | $1.06B | $889.48M | 18.7 % |
BioNTech (BNTX) publicó su última previsión de noviembre 3, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $1.96B - $2.19B para el período.
En comparación con la previsión anterior, BioNTech elevado redujo su previsión de ingresos desde un rango anterior de $1.86B - $2.21B.
BioNTech ha emitido 14 actualizaciones de orientación entre el enero 9, 2024 y el noviembre 3, 2026. During this period, the company raised its outlook 2 times and lowered it 6 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.97 | $-2.34 | $-2.52 | $-0.47 |
| Actual | $2.03 | $-2.58 | $-2.28 | $-0.38 |
| Surprise | +109.3% | -10.3% | +9.52% | +19.1% |
| Revenue | ||||
| Estimate | $1.17B | $182.0M | $214.6M | $889.5M |
| Actual | $1.48B | $122.8M | $138.0M | $1.06B |
| Surprise | +26.8% | -32.6% | -35.7% | +18.7% |
| Metric | Q4 '26E | Q1 '27E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-1.41 | $-2.44 |
| Revenue | ||
| Consensus | $511.9M | $164.8M |